Translational and clinical studies of target-based cancer therapy

International Journal of Clinical Oncology

Volumn 8, Issue 4, 2003, Pages 187-192

  Saijo, Nagahiro ^a   Nishio, Kazuto ^a   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER   (Japan)

Author keywords

Target based drug; Translational study

Indexed keywords

AFFINITAC; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYTARABINE; GEFITINIB; IMATINIB; INTERFERON; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PLATINUM; PRINOMASTAT; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SEMAXANIB; TANOMASTAT; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GENE THERAPY; HUMAN; METHODOLOGY; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG DESIGN; DRUG EVALUATION; HUMANS; MOLECULAR BIOLOGY; NEOPLASMS;

EID: 0141792178     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-003-0324-x     Document Type: Review

References (12)

1. Fukuoka M, Yano S, Giaccone G, et al. (2002) Final results from a phase II trial of ZD1839 (Iressa) for patients with advanced non small cell lung cancer (IDEAL-1). Pro ASCO 21:1188
2. Shepherd FA, Giaccone G, Seymour L, et al. (2002) Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20:4434-4439
3. Saijo N, Tamura T, Nishio K (2000) Problems in the development of target based drugs. Cancer Chemother Pharmacol 46:S43-S45
4. Saijo N, Tamura T, Nishio K, Yamamoto N (2001) New strategies for cancer therapy in the twenty-first century. Cancer Chemother Pharmacol 48:S102-S106
5. Saijo N, Tamura T, Nishio K (2003) Strategy for the development of novel anticancer drugs. Cancer Chemother Pharmacol (in press)
6. Fox E, Curt EA, Balis FM (2002) Clinical trial design for target-based therapy. The Oncologist 7:401-409
7. Sekine I, Tamura T, Kunitoh H, et al. (1999) Progressive disease rate as a surrogate endpoint of phase II trials of non-small cell lung cancer. Ann Oncol 10:731-733
8. Saijo N (2002) Translational study in cancer research. Internal Med 41:770-773
9. Saijo N, Sauseville E (2002) International discussion: new anticancer developments in the twenty-first century. Medical Asahi 31:13-19
10. Birmingham K (2002) What is translational research? Nature Med 8:647
11. Saijo N (2002) The molecular biology and signal transduction of epidermal growth factor receptor. New Developments in Lung Cancer 1:3-6
12. Saijo N, Blackledge G, Nakamura Y (2002) Round Table Meeting: strategy for cancer therapy. Cancer Molecular Target Based Therapy 1:8-16